This metabolic reprogramming mechanism induced by SOX2 could modulate sorts of malignant tumor cells to enhance aggressive phenotypes, drug resistance and metastatic ability, such as in melanoma and prostate cancer [40, 66]. This evidence concerns the gene SOX2 and prostate carcinoma.